These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 14658944)

  • 21. Patient outcomes within schizophrenia treatment: a look at the role of long-acting injectable antipsychotics.
    Bera RB
    J Clin Psychiatry; 2014; 75 Suppl 2():30-3. PubMed ID: 24919169
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Review and analysis of hospitalization costs associated with antipsychotic nonadherence in the treatment of schizophrenia in the United States.
    Sun SX; Liu GG; Christensen DB; Fu AZ
    Curr Med Res Opin; 2007 Oct; 23(10):2305-12. PubMed ID: 17697454
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The relationship between patient satisfaction and treatment outcomes in schizophrenia.
    Chue P
    J Psychopharmacol; 2006 Nov; 20(6 Suppl):38-56. PubMed ID: 17046986
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [The first long-acting atypical antipsychotic: new milestone in the treatment of schizophrenia].
    Faludi G
    Neuropsychopharmacol Hung; 2005 Mar; 7(1):22-7. PubMed ID: 16167464
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Interventions to improve antipsychotic medication adherence: review of recent literature.
    Dolder CR; Lacro JP; Leckband S; Jeste DV
    J Clin Psychopharmacol; 2003 Aug; 23(4):389-99. PubMed ID: 12920416
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-acting injectable formulations of antipsychotic drugs for the treatment of schizophrenia.
    Park EJ; Amatya S; Kim MS; Park JH; Seol E; Lee H; Shin YH; Na DH
    Arch Pharm Res; 2013 Jun; 36(6):651-9. PubMed ID: 23543652
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Model of Management (Mo.Ma) for the patient with schizophrenia: crisis control, maintenance, relapse prevention, and recovery with long-acting injectable antipsychotics (LAIs).
    Brugnoli R; Rapinesi C; Kotzalidis GD; Marcellusi A; Mennini FS; De Filippis S; Carrus D; Ballerini A; Francomano A; Ducci G; Del Casale A; Girardi P
    Riv Psichiatr; 2016; 51(2):47-59. PubMed ID: 27183509
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-acting injectable antipsychotics in the treatment of schizophrenia: their role in relapse prevention.
    Agid O; Foussias G; Remington G
    Expert Opin Pharmacother; 2010 Oct; 11(14):2301-17. PubMed ID: 20586707
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Switching antipsychotic therapies.
    Masand PS; Berry SL
    Ann Pharmacother; 2000 Feb; 34(2):200-7. PubMed ID: 10676829
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost-effectiveness Analysis of Aripiprazole Once-Monthly for the Treatment of Schizophrenia in the UK.
    Tempest M; Sapin C; Beillat M; Robinson P; Treur M
    J Ment Health Policy Econ; 2015 Dec; 18(4):185-200. PubMed ID: 26729007
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders.
    Dold M; Samara MT; Li C; Tardy M; Leucht S
    Cochrane Database Syst Rev; 2015 Jan; 1(1):CD009831. PubMed ID: 25592299
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summary.
    Kane JM; Leucht S; Carpenter D; Docherty JP;
    J Clin Psychiatry; 2003; 64 Suppl 12():5-19. PubMed ID: 14640142
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacokinetic profile and clinical efficacy of long-acting risperidone: potential benefits of combining an atypical antipsychotic and a new delivery system.
    Ereshefsky L; Mannaert E
    Drugs R D; 2005; 6(3):129-37. PubMed ID: 15869316
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Maintenance pharmacotherapy of schizophrenia: remission and the effectiveness of long-acting risperidone therapy].
    Sárosi A
    Neuropsychopharmacol Hung; 2006 Dec; 8(4):179-87. PubMed ID: 17211053
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-Acting Injectable Paliperidone Palmitate: A Review of Efficacy and Safety.
    Morris MT; Tarpada SP
    Psychopharmacol Bull; 2017 May; 47(2):42-52. PubMed ID: 28626271
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Symptom domains of schizophrenia: the role of atypical antipsychotic agents.
    Burton S
    J Psychopharmacol; 2006 Nov; 20(6 Suppl):6-19. PubMed ID: 17046984
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Academic highlights: guidelines for the use of long-acting injectable atypical antipsychotics.
    Keith SJ; Kane JM; Turner M; Conley RR; Nasrallah HA
    J Clin Psychiatry; 2004 Jan; 65(1):120-31. PubMed ID: 14744181
    [No Abstract]   [Full Text] [Related]  

  • 38. Strategies for transitioning therapy to aripiprazole from other antipsychotics in schizophrenia.
    Wisniewski CS; Robert S
    Ann Pharmacother; 2012; 46(7-8):1097-104. PubMed ID: 22811346
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Compliance in schizophrenia: predictive factors, therapeutical considerations and research implications].
    Misdrahi D; Llorca PM; Lançon C; Bayle FJ
    Encephale; 2002; 28(3 Pt 1):266-72. PubMed ID: 12091789
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-acting atypical injectable antipsychotics in the treatment of schizophrenia: safety and tolerability review.
    Cañas F; Möller HJ
    Expert Opin Drug Saf; 2010 Sep; 9(5):683-97. PubMed ID: 20690885
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.